{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:45:33Z","timestamp":1782722733508,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jpet.2026.104894","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:27:37Z","timestamp":1776814057000},"page":"104894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacology and nonclinical development of teplizumab, a first-in-class immunotherapy for delaying the onset of type 1 diabetes"],"prefix":"10.1016","volume":"393","author":[{"given":"Rao N.V.S.","family":"Mamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-3513","authenticated-orcid":false,"given":"Mark","family":"Peakman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schmider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Benstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Knecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Glascott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Sundermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8793-7848","authenticated-orcid":false,"given":"Jeffrey A.","family":"Bluestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpet.2026.104894_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.17925\/EE.2023.19.2.7","article-title":"Teplizumab in type 1 diabetes mellitus: an updated review","volume":"19","author":"Thakkar","year":"2023","journal-title":"touchREV Endocrinol"},{"key":"10.1016\/j.jpet.2026.104894_bib3","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3389\/fimmu.2017.01898","article-title":"Type 1 diabetes: a chronic anti-self-inflammatory response","volume":"8","author":"Clark","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104894_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4239\/wjd.v11.i1.13","article-title":"Current understandings of the pathogenesis of type 1 diabetes: genetics to environment","volume":"11","author":"Giwa","year":"2020","journal-title":"World J Diabetes"},{"issue":"11","key":"10.1016\/j.jpet.2026.104894_bib5","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.3390\/ijms24119220","article-title":"Advances in immunotherapeutic approaches to type 1 diabetes","volume":"24","author":"Cudini","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"suppl 1","key":"10.1016\/j.jpet.2026.104894_bib6","first-page":"S27","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jpet.2026.104894_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/cancers15041189","article-title":"Modulating T cell responses by targeting CD3","volume":"15","author":"Menon","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jpet.2026.104894_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpet.2026.104894_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtemb.2022.127040","article-title":"Antigen-specific immunotherapies in type 1 diabetes","volume":"73","author":"Zhang","year":"2022","journal-title":"J Trace Elem Med Biol"},{"issue":"10","key":"10.1016\/j.jpet.2026.104894_bib10","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41574-025-01128-6","article-title":"Type 1 diabetes mellitus prevention: present and future","volume":"21","author":"Henriques","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jpet.2026.104894_bib11","year":"2022","journal-title":"Food and Drug Administration"},{"issue":"5","key":"10.1016\/j.jpet.2026.104894_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7793","article-title":"Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes","volume":"1","author":"Long","year":"2016","journal-title":"Sci Immunol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104894_bib13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14712591003598843","article-title":"Teplizumab therapy for type 1 diabetes","volume":"10","author":"Masharani","year":"2010","journal-title":"Exp Opin Biol Ther"},{"issue":"20","key":"10.1016\/j.jpet.2026.104894_bib14","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1073\/pnas.0402295101","article-title":"Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3","volume":"101","author":"Kjer-Nielsen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2026.104894_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/HAB-1994-51-206","article-title":"Humanization of the murine anti-human CD3 monoclonal antibody OKT3","volume":"5","author":"Adair","year":"1994","journal-title":"Hum Antibodies Hybridomas"},{"issue":"2","key":"10.1016\/j.jpet.2026.104894_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4049\/jimmunol.138.2.648","article-title":"The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage","volume":"138","author":"Campana","year":"1987","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104894_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-025-06579-0","article-title":"Is the NOD mouse a good model for type 1 diabetes?","volume":"69","author":"Wong","year":"2026","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.jpet.2026.104894_bib18","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","article-title":"CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice","volume":"158","author":"Chatenoud","year":"1997","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104894_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2337\/diab.32.3.247","article-title":"Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity","volume":"32","author":"Kataoka","year":"1983","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.jpet.2026.104894_bib20","first-page":"1907","article-title":"Modified anti-CD3 therapy in psoriatic arthritis: a phase I\/II clinical trial","volume":"29","author":"Utset","year":"2002","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104894_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004729","article-title":"Genetic variation and population substructure in outbred CD-1 mice: implications for genome-wide association studies","volume":"4","author":"Aldinger","year":"2009","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.jpet.2026.104894_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177492","article-title":"Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes","volume":"134","author":"Lled\u00f3-Delgado","year":"2024","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jpet.2026.104894_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1615\/CritRevImmunol.v20.i4.20","article-title":"Internalization and intracellular fate of TCR-CD3 complexes","volume":"20","author":"Alcover","year":"2000","journal-title":"Crit Rev Immunol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526010931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526010931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:07:04Z","timestamp":1782720424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526010931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0022356526010931"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104894","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology and nonclinical development of teplizumab, a first-in-class immunotherapy for delaying the onset of type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104894"}}